Skip to main content

Agarwal Shefali

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Agarwal Shefali as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

FATE Fate Therapeutics Inc

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 8, 2022 (view filing)Jun 71 dayAgarwal ShefaliDirectorSSale−841$21.89−$18.4K−31.4%1.84K after
Jun 8, 2022 (view filing)Jun 35 daysAgarwal ShefaliDirectorSSale0–$00.0%2.68K afterAmended

EPZM Epizyme, Inc.

Other: See Remarks4 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 9, 2022 (view filing)Feb 72 daysAgarwal ShefaliSee RemarksSSaleCommon Stock, par value $0.0001−1.06K$1.50−$1.59K−0.7%156.4K after
Feb 4, 2022 (view filing)Feb 22 daysAgarwal ShefaliSee RemarksSSaleCommon Stock, par value $0.0001−2.64K$1.37−$3.62K−1.6%157.4K after
Jan 28, 2022 (view filing)Jan 262 daysAgarwal ShefaliSee RemarksSSaleCommon Stock, par value $0.0001−2.92K$2.02−$5.90K−1.8%160.1K after
Dec 7, 2021 (view filing)Dec 61 dayAgarwal ShefaliSee RemarksSSaleCommon Stock, par value $0.0001−1.78K$2.93−$5.22K−1.1%163.0K after